CombinADO: Evaluation of an Intervention Aimed at Improving HIV Outcomes Among Adolescents and Young Adults Living With HIV in Mozambique

HIV Clinical Trial

Official title:

CombinADO: a Cluster-randomized Controlled Trial to Compare the Efficacy, Uptake, Feasibility and Acceptability of the CombinADO Strategy Versus Optimized Standard of Care on Viral Suppression, ART Adherence and Retention in HIV Care Among Adolescents and Young Adults Living With HIV Ages 10-24yrs in Nampula Province, Mozambique

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04930367
• Other study ID #: AAAT5971
• Secondary ID: 4UH3HD096926-03
• Status: Recruiting
• Phase: N/A
• Start date: September 13, 2021
• Est. completion date: July 2024

Study information

• Verified date: September 2023
• Source: Columbia University
• Contact: Joana Falcao, MPH
• Phone: +258 21315170
• Email: jrf2191[@]cumc.columbia.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a cluster-randomized trial designed to compare the effectiveness of the CombinADO strategy versus optimized standard of care (SOC) on viral suppression, antiretroviral therapy (ART) adherence and retention in HIV care among adolescents living with HIV (ALHIV) ages 10 to 24 years attending participating health facilities. Clinics are the units of intervention allocation and randomization. The control condition will be implemented at all facilities (n=12) participating in the trial. The enhanced intervention condition will be superadded to this at a randomly selected half (n=6) of facilities. The goal of this study is to learn whether an enhanced, tailored intervention helps AYAHIV do better with their HIV care (take their medications, stay in care) than the usual care that they receive.

Description:

HIV burden among adolescents and young people worldwide is substantial, with an estimated 1.7 million adolescents aged 10-19 years living with HIV in 2019, and 460,000 adolescents aged 15-24 newly infected reported in the same year. Adolescent girls continue to be disproportionately affected, accounting for 56% of new infections worldwide. With increased availability of antiretroviral therapy (ART), pediatric mortality has decreased and healthcare workers (HCW) are now challenged to meet the complex needs of the large number of surviving youth who must cope with HIV as a chronic, highly stigmatized, and transmittable illness. There are 1.8 billion people between ages 10 and 24 and it is projected that the number of people <20 years will double by 2030. In sub-Saharan Africa (SSA), youth aged 10-24 years comprise 30-35% of the countries' population. Failure to prevent new HIV infections among adolescents will result in increased numbers of adolescents and young adults living with HIV (AYAHIV) who will strain health and social service systems as they transition to adulthood.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2400
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 24 Years

Eligibility

Adolescents and young adults living with HIV (AYAHIV):

Inclusion Criteria:

1. HIV-positive, per medical records and confirmed by health facility staff

2. Age 10 to 24 years

3. Registered as a patient at study site

4. Aware of HIV+ status

5. Provision of signed and dated informed consent form

6. For adolescents under 18 years of age, informed assent and parental informed consent to participate in the study

7. Stated willingness to comply with all study procedures

Exclusion Criteria:

1. Has an acute medical condition requiring immediate medical care Caregivers of AYAHIV:

Inclusion Criteria:

1. Age 18 years and older

2. Attending a caregiver-specific support group

3. Willingness to be audio-recorded Healthcare Workers (HCW) and Key Informants (KI):

Inclusion Criteria:

1. Age 18 years and older

2. Involved in the provision, management, or oversight of adolescent-focused HIV services at the 12 specified study sites

3. Willingness to be audio-recorded For all study participants (AYAHIV, caregivers, HCW and KI): Exclusion Criteria: Any other condition, including but not limited to alcohol or substance abuse and uncontrolled medical condition and/or allergies, that, in the opinion of the study team, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives would make the patient unsuitable for the study or unable/unwilling to comply with the study requirements.

Related Conditions & MeSH terms

• HIV

Intervention

Behavioral:
• Radio Ads
Engaging radio mini shows that address community stigma and medical literacy through busting common myths with humor and building empathy with heartfelt storytelling.
• Community Sensitization Campaign
Large-scale, infographic billboards and posters located in public areas and secondary schools to address stigma, medical literacy and promote community support for AYAHIV.
• Informational Posters
Large-scale, infographic posters located in clinic waiting areas to normalize HIV and build confidence in treatment.
• Motivation Walls
Interactive, patient-generated posters located in the consultation room where patients can post words and phrases about themselves and their futures.

Other:
• Pill Container
A discreet pill container to support ART adherence.
• CombinADO-specific training for healthcare workers
Comprehensive in-service training for healthcare workers focused on the needs of adolescents and young adults living with HIV
• One Stop Shop Model of Care
Model of care that allows adolescents and young adults living with HIV to access a complete set of services, including HIV care, in one central location.
• Treatment Toolkit
A guide to clinic visits and discussions on ART and viral load monitoring to help healthcare workers better communicate with patients.
• Self-reflection Kit
A simple handout for healthcare workers to help patients reflect on their ART progress and understand the concept of viral load as a measure of ART success.

Behavioral:
• Peer Support
Peer exposure to examples of adolescents and young adults openly living with HIV (AYAHIV) and; opportunities to share their experiences with HIV in one-on-one interactions with other AYAHIV during clinic visits.
• Informational and motivational Video
An informational and motivational video that in simple language with engaging graphics that a) demystifies and simplifies HIV, ART, and viral load and; b) emphasizes that people can live long, healthy lives.
• Support groups- caregivers of adolescents and young adults living with HIV
A learning, support, and empowerment group for caregivers of adolescents and young adults living with HIV (AYAHIV). Through monthly gatherings, the program aims to foster confidence, and equip caregivers with strategies to support AYAHIV adherence journey.
• Support groups- adolescents and young adults living with HIV
A peer-to-peer learning, support, and empowerment group to address loss of hope and improve medical literacy. Through biweekly gatherings, the program aims to foster belonging and confidence, equipping young people and caregivers with strategies to navigate the adherence journey.
• Mental health screening and linkage to adolescent-focused mental health support
HCWs will be trained in the use of a brief mental health screening tool focusing on depression, anxiety, and post-traumatic stress disorder. Mental health service providers at each facility will be trained and supported to provide diagnostic and mental health support to youth with positive screens who agree to further evaluation.

Locations

Country	Name	City	State
Mozambique	Cs 1 de Maio	Nampula
Mozambique	Cs 25 Setembro	Nampula
Mozambique	Cs Alua	Nampula
Mozambique	Cs Anexo Psi	Nampula
Mozambique	Cs Malema	Nampula
Mozambique	Cs Muhala Expansao	Nampula
Mozambique	Cs n1 Nacala Porto	Nampula
Mozambique	Cs Nametil	Nampula
Mozambique	Cs Namialo	Nampula
Mozambique	Cs Namicopo	Nampula
Mozambique	HG Marere	Nampula
Mozambique	HR Angoche	Nampula

Sponsors (3)

Lead Sponsor	Collaborator
Columbia University	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Cape Town

Country where clinical trial is conducted

Mozambique, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of adolescents and young people living with HIV (AYAHIV) with viral suppression (Viral load <50 copies/ml)	Viral suppression among AYAHIV at intervention versus control sites	12 months post intervention implementation
Secondary	Proportion of eligible adolescents and young people living with HIV (AYAHIV) attending clinic in a 90 day window from end of intervention implementation, as assessed at 12 months post intervention.	Retention in HIV care & treatment among AYAHIV at intervention versus control sites	12 months post intervention implementation
Secondary	Self-reported adherence measured using 3-item adherence scale (mean score)	Self-reported ART adherence among adolescents and young people living with HIV at intervention versus control sites will be measured using a three-item adherence scale. The three items include (1) an assessment of the number of days with missed ART doses in the preceding 30 days [0-30 days]; (2) a scale rating of how good a job you did taking your medicines in the preceding 30 days (never/rarely/sometimes/usually/almost always/always) and (3) a scale rating of how often you took your medicines the way you were supposed to in the preceding 30 days (very poor/poor/fair/good/very good/ excellent).; For analyses using raw scores, item responses for the three adherence items will be linearly transformed to a 0-100 scale with zero being the worst adherence, and 100 representing perfect adherence. The mean of the three scores are then taken to get an equally weight aggregate scale score. An overall mean from the scores from all participants will be reported.	12 months post intervention implementation
Secondary	Proportion of participants with detectable antiretroviral (ARV) on dried blood spot (DBS) specimen	ART adherence among among adolescents and young people living with HIV (AYAHIV) at intervention versus control sites, ARV levels	12 months post intervention implementation